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Abstract
The genes PTPN22 and HLA-DRB1 have been found by a number of studies to confer an increased
risk for rheumatoid arthritis (RA), which indicates that both genes play an important role in RA
etiology. It is believed that they not only have strong association with RA individually, but also
interact with other related genes that have not been found to have predisposing RA mutations. In
this paper, we conduct genome-wide searches for RA-associated gene-gene interactions that
involve PTPN22 or HLA-DRB1 using the Genetic Analysis Workshop 16 Problem 1 data from the
North American Rheumatoid Arthritis Consortium. MGC13017, HSPCAL3, MIA, PTPNS1L,a n d
IGLVI-70,w h i c hs h o w e da s s o c i a t i o nw i t hR Ai np r e v i o u ss t u d i e s ,h a v eb e e nc o n f i r m e di no u r
analysis.
Background
Rheumatoid arthritis (RA), MIM 180300, is a symmetric,
chronic polyarticular arthritis that affects 0.5-1% of the
population. It primarily causes progressive joint destruc-
tion that leads to restriction of daily activities and
deterioration of qualityoflife. Although the pathogenesis
of RA has not been fully explained, it is thought to be a
complex disease caused by a combination of multiple
genetic and environmental factors. Previous studies have
indicated a few genetic regions that might be in
association with RA, most notably HLA-DRB1 and
PTPN22.T h eHLA region on 6p21 is well known for
showing the strongest association with RA. The evidence
so far has particularly emphasized to the HLA-DRB1 gene
[1]. The PTPN22 gene (1p13.3-p13.1) has also repeatedly
shown association to RA, in a modest way [2]. Despite
these findings, progress in identifying new genes asso-
ciated with the susceptibility to RA has been limited. An
explanation is that individual contribution of each gene
might besmall and the traditional methods onlytesteach
marker individually, considering no interaction between
markers. It is believed that important information is
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methods are used to study gene-gene interactions that
involve HLA-DRB1 or PTPN22 on a whole-genome scale.
Association scores between pair-wise single-nucleotide
polymorphism (SNP)-SNP interactions and the RA
affection status are aggregated into measures of gene-
gene interaction effects, using the Genetic Analysis
Workshop 16 Problem 1 whole-genome data.
Data collected in a whole-genome association study
usually consist of dense SNPs, with multiple SNPs
covering a gene. SNP-based analysis is pruned for noise
and local dependence, at the same time increasing
computational burden. Lo et al. [3] carried out a gene-
based analysis on breast cancer candidate genes and
demonstrated that using genes as analysis units leads to
more stable results and higher interpretability. In this
paper, we use a similar gene-based analysis to study
interactions between HLA-DRB1 or PTPN22 and each of
the 23,580 genes in the genome for association with RA
susceptibility.
Methods
Data
The data from Genetic Analysis Workshop 16 Problem 1
consist of 868 cases and 1194 controls from the North
Rheumatoid Arthritis Consortium (NARAC), with geno-
types on 545,080 SNPs. The percentage of missing data
was not high, so we were able to impute the missing
values using the computer program fastPhase [4].
Using the whole-genome map of breast cancer data from
Cancer Genetic Markets Susceptibility [5], RA SNPs were
mapped to genes. SNPs that did not belong to any genes
were ignored and different genes with overlapping SNPs
were considered separately. For example, if all the SNPs
of gene A had been included in gene B, we only
considered the “bigger” gene B. After the mapping, we
identified 23,580 genes on the 22 chromosomes,
including HLA-DRB1 (5 SNPs) and PTPN22 (12 SNPs).
For each of these 23,580 genes, we then studied the
interaction with HLA-DRB1 or PTPN22 in terms of
association with RA affection status.
Association measure of gene-gene interaction
We first introduce the genotype-trait distortion statistic
[6] that measures the joint association of multiple SNPs
with a disease outcome. Considering k SNPs, each with
three possible genotypes, there are 3k possible geno-
types. Genotype-trait distortion is defined as follows
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where nD, n, nu, s are counts of cases and controls with
genotype s,a n dnD, nu are the total number of cases and
controls. When applied to a single SNP, v measures the
marginal effect of a SNP. If the joint effect of two SNPs
exceeds their individual marginal effects, we regard it as
an evidence of interaction. As used in Lo et al. [3] to
capture interaction signals at SNP level, we define the
SNP-level ratio statistic as
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where id is the d
th SNP of gene i, je is the e
th SNP of gene j,
and “∨“ means maximum of the two values. Here
vv ij de ∨ captures the marginal effects of SNPs id and je.
To evaluate the effect of each gene pair (i, j), we define
the following gene-level statistics for the marginal effect
and interaction signal. Assume gene i has mi SNPs and
gene j has mj SNPs. The first statistic for the marginal
effect, called the average maximum marginal M,i s
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The statistic for gene-gene interaction based on the SNP
level ratios is defined as
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This term is called the “mean interaction ratio” between
two genes, or simply, the mean ratio.
Evaluation of significance
Because the distribution of the mean ratio statistic is
unknown, we used permutations to evaluate the
significance of the gene-gene interactions. We carried
out 1000 permutations and calculated the statistics
described above on each HLA-DRB1-gene pair and
PTPN22-gene pair using the original data and the
permuted data. Because HLA-DRB1 and PTPN22 have
different numbers of SNPs and potentially different local
dependence among the SNPs, we evaluated the gene
pairs with HLA-DRB1 or PTPN22 separately.
Using results from the permuted data, we observe that
the magnitude of the gene-gene interaction measures
(i.e., mean ratio) depends on the magnitude of the
marginal effects under the null hypothesis. Therefore, the
evaluation of significance for interaction between a pair
of genes should be conditioning on their marginal effect
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Mij against Rij on the permuted data. This gave us 1000
sets of 23,580 points to create a joint distribution of M
and R under the null hypothesis of no association. We
first used the following curve method [3] to construct
significance threshold for gene-gene interactions that
depends on the values of the marginal effect statistic M.
Curve method
We placed all points (23,580 × 1000 = 23,580,000
points) obtained from the 1000 permutations on the
(M, R) plane. The values of the M coordinate were
separated into 10,000 bins, each with 2358 points. Each
bin was represented by a point with coordinates (M*,
R*), where R* was the 99.9% percentile of the R scores
that fell into this bin and M* was the midpoint of this
bin. A smoothing curve, using a spline with 10 degrees of
freedom, was fitted to these 10,000 points that repre-
sented the 99.9% significance threshold at each M level.
Gene pairs (i, j)w i t h( M, R) coordinates above this curve
were selected as significant interactions.
Lo et al. [3] also proposed a rank method for evaluating
significance that has lesser distribution assumption than
the curve method described above. We used both
methods to evaluate the significance of gene-gene
interactions.
Rank method
The rank method also depends on the bins based on the
marginal M values as the curve method does. Within
each bin, we assigned rank values to the 2358 points
according to their R values (decreasing order: the highest
value receives rank 1). For each gene pair, we compared
the rank received by the score based on the original data
with the ranks received by the permuted values. The
p-value of this gene pair was then the proportion of
the permuted values with rank values lower than the
observed data.
Results
Figure 1 displays the two-dimensional (M, R)p l a n ef o r
gene-HLA-DRB1 interactions and gene-PTPN22 interac-
tions. The observed data are plotted using red dots. The
black dots are the threshold calculated within 10,000
bins by the curve method using permuted data as
described in the previous section. For interactions with
HLA-DRB1, the marginal effect is much greater than that
is simulated in permutations. This is due to strong
marginal signals at HLA-DRB1 in the current data. As a
result, we had no permuted points that were close to the
observed points for calculating reliable selection thresh-
old conditional on the observed M values. Therefore, we
extended the curve threshold of the last bin to the levels
of observed M values. This is a conservative extrapola-
tion because the threshold decreases as M increases.
Based on this conservative threshold, zero gene-pairs
were selected to have significant interaction with
HLADRB1. The rank method, on the other hand,
suggested 79 genes to be significant at 0.1% level.
However, because the rank values of the observed values
were based on the last wide bin that stretched from the
top 0.01% of the permutations to the maximum of the
observed values, the adjustment to local distribution by
using the rank method was not reliable. Due to this
concern, in this paper we report only results based on the
curve method.
For interaction with PTPN22, we also observed strong
marginal signals from PTPN22 but they are not so
dominating as HLA-DRB1. The distribution of (M, R)
points from the permutations overlapped slightly with
the scatter of the observed data, which allowed us to
derive a reliable selection threshold for gene pairs with
relatively lower observed M values. Using the curve
method, 24 genes were selected to have significant
interaction with PTPN22 at 0.1% level (Table 1). The loci
of these genes overlap with important RA susceptibility
Figure 1
Observed (M, R) plane with curve threshold
computed from permutations. Red dots are observed
values (M, R) for gene pairs studied. The black dots are the
99.9% threshold for each bin calculated from 1000
permutations. The dark blue curve is the smoothing spline
fitted to the 99.9% bin-thresholds. The right panel displays
the same data as the left column with smaller scale to focus
on the tail of the scatter.
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CDKN2AIPNL)i sCDKN2A interacting protein N-term-
inal like according to the NCBI gene database, while
CDKN2A has been found to encode proteins that inhibit
CDK4 kinase. Nonomura et al. [7] studied the role of
CDK4 in the production of inflammatory molecules
among subjects with RA and concluded that this protein
was associated with the mediation of inflammation.
HSPCAL3 (official symbol: HSP90AA2) is inferred as
heat shock protein 90-kDa alpha (cytosolic), class A
member 2. Hayem et al. [8] studied stress proteins such
as HSP90 kDa in the serum of RA patients and found that
it may be related to articular prognosis in RA. In the
recent study by Vandooren et al. [9], the regulation of
MIA in RA was observed and studied. PTPNS1L is
inferred to be protein tyrosine phosphatase, nonreceptor
type substrate 1-like and potentially has similar but
unknown functionality as some proteins in the same
family as PTPN22. IGLVI-70,a tt h es a m el o c u so f
PTPNS1L, has been thought to be related to the
immunoglobulin proteins, which have been found to
play important roles in the RA pathology.
Conclusion
In this paper, we studied RA-associated interactions
between 23,580 genes on the genome and two important
RA candidate genes, HLA-DRB1 and PTPN22.I n t e r a c t i o n
signals were first calculated at the SNP level and then
aggregated into gene-based measurements. Significance
was evaluated using permutations. A number of sig-
nificant gene-PTPN22 interactions were found to be
associated with the disease status of RA, some of which
agreed with previous studies. Through this project, we
also found the methods of Lo et al. [3] work better when
the marginal signals genes were weak. When the
marginal effects of the candidate gene are extremely
strong, for example, the odds ratio is greater than 6, the
interaction with other genes becomes harder to capture.
Further research is needed to address this issue.
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